GET DAILY SIGNALSHeron Therapeutics (HRTX): Assessing the +440% Upside to the $2.00 Analyst Target
Key Takeaways
- The central price target for Heron Therapeutics, Inc. (HRTX) is $2.00, based on the arithmetic mean of the current verifiable analyst price targets rather than a single firm's view.
- At a latest price near $0.37, reaching $2.00 would require a gain of roughly 440%, a very large move for a sub-$1 biotechnology stock.
- The analyst range has narrowed sharply: objectives that once spanned roughly $4 to $6 were reset toward $2.00 after a patent setback involving Cinvanti, with several firms moving to Hold ratings.
- The strongest supporting factors are the announced sale of substantially all assets to CorMedix (CRMD), retained net operating loss carryforwards, and a narrowing quarterly loss.
- The biggest risks include continued revenue decline, a now asset-light holding structure, Hold ratings, and uncertainty over how the company will redeploy its proceeds.
- For additional detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for each.
- Explore Trending AI Robots to see AI-driven strategies scanning markets for changing conditions.
Analyst Price Targets and Consensus View
Heron Therapeutics is a commercial-stage biotechnology company whose acute care portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. After a court decision adverse to its Cinvanti patents in mid-2026, sell-side price targets were reset sharply lower, and coverage thinned. H.C. Wainwright cut its objective from $4 to $2.00 in June 2026 before moving its rating from Buy to Hold in August 2026, while Needham downgraded the stock to Hold without a price target in June 2026.
As a result, the current, verifiable analyst price target is essentially a single $2.00 objective, and independent aggregators report an average analyst price target near $2.00. The $2.00 figure is used here as the central target because it is the only current, attributable target; earlier Northland Securities ($4) and Jefferies ($5) targets date back to late 2025 and are no longer current. This is a thin and cautious consensus rather than a robust one, so the target should be read as a directional reference, not a forecast. From what I see, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
HRTX closed around $0.37 on November 9, 2026, up roughly 26% in a single session after the company disclosed a definitive agreement to sell substantially all of its assets to CorMedix for $145 million in cash and stock plus up to $55 million in potential earn-out payments. The shares remain near the low end of a 52-week range of about $0.26 to $1.58, with a market capitalization near $70 million.
Moving from $0.37 to $2.00 would require an advance of about 440%, a very large percentage move. Because Heron will retain its roughly $2.3 billion of net operating loss carryforwards, the CorMedix shares it receives, future royalties and earn-outs, and cash on hand, the path to any substantially higher valuation now depends less on product revenue and more on how the board redeploys proceeds into new businesses or assets — an outcome that is inherently difficult to model.
What Could Support a Move Toward the Target
The CorMedix transaction gives Heron a clearer, cash-generating path forward. It converts an uncertain operating business into a balance of cash, equity, and contingent value, while preserving significant tax assets that could shelter future income. Third-quarter results also showed a shrinking loss — $5.0 million versus $17.5 million a year earlier — as gross margins held up despite lower revenue. Any value-creating acquisition, investment, or strategic transaction announced after closing could re-rate the shares substantially, as could favorable developments in patent appeals or royalties on the divested products.
What Could Prevent the Target From Being Reached
Reaching $2.00 is a demanding objective. Product revenue has been declining, with third-quarter net product sales of $35.3 million down from $38.2 million a year earlier, and the divestiture removes the core operating business. The stock trades below $1, carries a Hold-leaning consensus, and faces genuine uncertainty about what Heron will become after closing. Execution risk on a value-creating redeployment of capital, dilution risk, and the possibility that the retained assets simply trade at a discount to their theoretical worth could keep the shares far below the $2.00 target for an extended period.
Technical Levels and Market Structure
HRTX trades well below its 52-week high near $1.58 and just above its 52-week low near $0.26. The $1.00 level represents both a psychological threshold and a meaningful round-number barrier, while the recent session high near $0.42 is an early short-term resistance zone. As a sub-$1 name, the stock also carries the structural overhang of potential Nasdaq listing-compliance considerations, which can influence institutional participation and liquidity.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though no single firm's horizon is stated here, and the thin coverage makes the $2.00 figure less precise than a typical consensus. Investors should watch for closing of the CorMedix transaction and its terms, any subsequent strategic transaction or capital deployment, the status of patent appeals, quarterly updates on retained royalties and earn-outs, and any renewed analyst coverage or target revisions following the deal.
AI Daily Buy/Sell Signals
In my own analysis of names like HRTX, I regularly review Tickeron’s AI Daily Buy/Sell Signals. These tools apply artificial intelligence to monitor thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. For volatile small-cap biotech names, the signals provide an additional data-driven perspective that complements traditional research without replacing it.
Final Assessment
The $2.00 central target, derived from the current analyst price target, sits roughly 440% above the latest price near $0.37 — a very large move. Support comes from the CorMedix asset sale, retained tax attributes, and a narrowing loss, while the principal obstacles are declining revenue, an asset-light post-deal structure, Hold ratings, and execution uncertainty around redeploying proceeds. With analyst coverage thin and targets recently reset lower, investors should treat $2.00 as a reference point, not a likely near-term outcome, and monitor deal closing and capital-allocation decisions as the key catalysts. I’m watching this closely for any post-deal updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for HRTX turns negative, indicating new downward trend
HRTX saw its Momentum Indicator move below the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 73 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for HRTX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 32 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
HRTX moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HRTX crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where HRTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTX advanced for three days, in 181 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
HRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 109 of 141 cases where HRTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.496) is normal, around the industry mean (3.498). P/E Ratio (-1.542) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.387) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. HRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of polymer technologies
Industry Biotechnology
Advertisement